• LAST PRICE
    5.2700
  • TODAY'S CHANGE (%)
    Trending Up0.0900 (1.7375%)
  • Bid / Lots
    5.1700/ 1
  • Ask / Lots
    5.2200/ 10
  • Open / Previous Close
    5.1200 / 5.1800
  • Day Range
    Low 4.9300
    High 5.2750
  • 52 Week Range
    Low 2.2000
    High 6.5476
  • Volume
    354,892
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 5.18
TimeVolumeALDX
09:32 ET97495.13
09:33 ET9005.06
09:35 ET142504.97
09:37 ET62844.95
09:39 ET48644.9304
09:42 ET16174.96
09:44 ET29004.975
09:46 ET27735
09:48 ET58985.01
09:50 ET5665
09:51 ET30775
09:53 ET15095.005
09:55 ET4495.015
10:02 ET54945.01
10:04 ET117655.06
10:06 ET37005.08
10:08 ET1005.07
10:09 ET4005.08
10:11 ET17995.1
10:13 ET6005.11
10:18 ET2005.1
10:20 ET18265.08
10:22 ET3005.065
10:24 ET54755.045
10:27 ET13585.07
10:29 ET119885.11
10:31 ET4005.11
10:33 ET2005.12
10:36 ET2005.1
10:42 ET2515.1
10:44 ET6005.08
10:45 ET18175.13
10:47 ET72475.1699
10:49 ET1965.17
10:51 ET1005.18
11:02 ET3005.1984
11:03 ET20615.19
11:05 ET1005.195
11:07 ET27185.2199
11:12 ET9275.18
11:23 ET64425.1915
11:25 ET4005.19
11:34 ET9005.19
11:36 ET41005.2
11:38 ET4555.22
11:39 ET2125.23
11:43 ET8005.21
11:50 ET5005.2
11:52 ET12005.21
11:54 ET10005.23
11:57 ET1005.22
12:01 ET16365.21
12:03 ET1215.21
12:08 ET3005.19
12:10 ET208585.121
12:12 ET1005.16
12:14 ET9415.1833
12:17 ET15285.19
12:26 ET1025.1801
12:32 ET125445.1403
12:33 ET1005.145
12:37 ET15485.15
12:39 ET9975.1531
12:42 ET1005.18
12:46 ET4005.1507
12:48 ET4005.16
12:53 ET1005.17
12:55 ET1005.16
12:57 ET2455.16
01:02 ET2005.17
01:04 ET6425.17
01:11 ET2455.17
01:15 ET4005.1799
01:20 ET1005.18
01:22 ET1415.175
01:24 ET4385.18
01:26 ET1005.2
01:31 ET10795.18
01:33 ET2775.175
01:36 ET1005.175
01:38 ET21005.18
01:40 ET1005.1802
01:42 ET52135.19
01:44 ET12445.19
01:45 ET3005.21
01:51 ET9625.2009
01:54 ET5995.24
01:58 ET2005.24
02:02 ET12005.24
02:03 ET8595.2594
02:05 ET5005.25
02:20 ET2275.23
02:21 ET13485.205
02:25 ET10055.22
02:27 ET49805.22
02:32 ET1005.23
02:38 ET1005.22
02:39 ET1005.22
02:41 ET20945.24
02:45 ET2095.24
02:50 ET9295.23
02:52 ET1005.22
02:54 ET3005.2203
02:56 ET1005.22
02:57 ET4005.21
02:59 ET11325.205
03:01 ET4005.19
03:06 ET5005.2
03:08 ET33685.22
03:15 ET2555.235
03:17 ET16195.21
03:19 ET7365.21
03:21 ET1005.22
03:24 ET20945.23
03:28 ET2105.245
03:30 ET38245.26
03:32 ET11845.25
03:35 ET3035.24
03:39 ET8005.235
03:42 ET29605.245
03:44 ET17005.225
03:46 ET7005.23
03:50 ET1005.24
03:51 ET26395.23
03:53 ET2005.23
03:55 ET10965.25
03:57 ET108275.265
04:00 ET390475.27
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesALDX
Aldeyra Therapeutics Inc
307.8M
-8.3x
---
United StatesRZLT
Rezolute Inc
304.2M
-4.1x
---
United StatesDSGN
Design Therapeutics Inc
301.2M
-6.2x
---
United StatesCMPS
Compass Pathways PLC
320.2M
-2.1x
---
United StatesBMEA
Biomea Fusion Inc
320.4M
-2.2x
---
United StatesNAUT
Nautilus Biotechnology Inc
322.7M
-4.7x
---
As of 2024-11-05

Company Information

Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.

Contact Information

Headquarters
131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
Phone
781-761-4904
Fax
302-636-5454

Executives

Independent Chairman of the Board
Richard Douglas
President, Chief Executive Officer, Director
Todd Brady
Principal Financial Officer and Principal Accounting Officer
Michael Alfieri
Chief Development Officer
Stephen Machatha
Independent Director
Ben Bronstein

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$307.8M
Revenue (TTM)
$0.00
Shares Outstanding
59.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.38
EPS
$-0.64
Book Value
$2.02
P/E Ratio
-8.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.